Rezultati pretrage - Rebecca Kristeleit

Detaljiziraj rezultate
  1. 1
    Optimal treatment for relapsing ovarian cancer

    Optimal treatment for relapsing ovarian cancer od JA Ledermann, Rebecca Kristeleit

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  2. 2
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions od Gottfried E. Konecny, Rebecca Kristeleit

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  3. 3
    Homologous recombination deficiency and ovarian cancer

    Homologous recombination deficiency and ovarian cancer od Jonathan A. Ledermann, Yvette Drew, Rebecca Kristeleit

    Izdano 2016
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  4. 4
    Mainstreamed genetic testing for women with ovarian cancer: first-year experience

    Mainstreamed genetic testing for women with ovarian cancer: first-year experience od Belinda Rahman, Anne Lanceley, Rebecca Kristeleit, Jonathan A. Ledermann, Michelle Lockley, Mary McCormack, Tim Mould, Lucy Side

    Izdano 2018
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    The Tumor Microenvironment of Clear-Cell Ovarian Cancer

    The Tumor Microenvironment of Clear-Cell Ovarian Cancer od Michael-John Devlin, Rowan Miller, Florian Laforêts, Panoraia Kotantaki, Dale W. Garsed, Rebecca Kristeleit, David D.L. Bowtell, Jacqueline McDermott, Eleni Maniati, Frances R. Balkwill

    Izdano 2022
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors od Geoffrey I. Shapiro, Rebecca Kristeleit, Howard A. Burris, Patricia LoRusso, Manish R. Patel, Yvette Drew, Heidi Giordano, Lara Maloney, Simon P. Watkins, Sandra Goble, Sarah Jaw‐Tsai, Jim Xiao

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

    First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors od André T. Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L. Rhoda Molife, Rebecca Kristeleit, Ann Parker, Isabel Casamayor, Muyibat Olaleye, Anna Mais, Bernhard Hauns, Vera Strobel, Bernd Hentsch, Johann S. de Bono

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovar... od Rebecca Kristeleit, Ірина Давиденко, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J. Goodheart, В. А. Горбунова, C A Penning, Jack Shi, Xiangdong Liu, Robert Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J. Schilder

    Izdano 2017
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer od Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

    A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors od Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, Matthew Tall, Adam Stewart, Florence I. Raynaud, Michelle D. Garrett, Martin Toal, Leon Hooftman, Johann S. de Bono, Jaap Verweij, Ferry A.L.M. Eskens

    Izdano 2012
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer od Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A. McNeish, Rosalind Glasspool, Marcia Hall, René L. Roux, Agnieszka Michael, Andrew R. Clamp, Gordon C. Jayson, Rebecca Kristeleit, Susana Banerjee, Anita Mansouri

    Izdano 2024
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer

    Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer od Rebecca Kristeleit, Michael-John Devlin, Andrew R. Clamp, Charlie Gourley, René L. Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsell, Rowan Miller

    Izdano 2025
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

    Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced... od Johann S. de Bono, Rebecca Kristeleit, Anthony W. Tolcher, Peter C.C. Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan B. Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik

    Izdano 2008
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers od Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, Andrés Redondo, Angela George, Jane Yuet Ching Hui, Aicha Seiller, Mario Liste-Hermoso, J. Willis, Colby S. Shemesh, Jim Xiao, Kevin K. Lin, Luciana Molinero, Yinghui Guan, Isabelle Ray‐Coquard, Linda Mileshkin

    Izdano 2024
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer

    ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer od Rebecca Kristeleit, Domenica Lorusso, Ana Oaknin, Tamar Safra, Elizabeth M. Swisher, Igor Bondarenko, Tomasz Huzarski, Jaroslav Klát, Vladimir Moiseyenko, Ròbert Póka, Luciana Spillari Viola, Chris Tankersley, Lara Maloney, Sandra Goble, Caro Unger, A. Dowson, Heidi Giordano, Amit M. Oza

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Detection of circulating tumour cell clusters in human glioblastoma

    Detection of circulating tumour cell clusters in human glioblastoma od Ilona Krol, Francesc Castro-Giner, Martina Maurer, Sofia Gkountela, Barbara M. Szczerba, Ramona Scherrer, Niamh Coleman, Suzanne Carreira, Felix Bachmann, Stephanie Anderson, Marc Engelhardt, Heidi A. Lane, T.R. Jeffry Evans, Ruth Plummer, Rebecca Kristeleit, Juanita Lopez, Nicola Aceto

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

    A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advance... od Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study

    O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study od Rebecca Kristeleit, Alla Lisyanskaya, А. А. Феденко, Mikhail Dvorkin, Andréia Cristina de Melo, Y. Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, M. Nechaeva, Francesco Raspagliesi, Giovanni Scambia, David Cibula, Ròbert Póka, Ana Oaknin, Tamar Safra, Beata Maćkowiak-Matejczyk, Ling Ma

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors od Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, María Vieito, Rowan Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason A. Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert

    Izdano 2022
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma

    Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma od Susana Banerjee, Gaia Giannone, Andrew R. Clamp, Darren Ennis, Rosalind Glasspool, Rebecca Herbertson, Jonathan Krell, Ruth Riisnaes, Hasan Mirza, Zhao Cheng, Jacqueline McDermott, Clare Green, Rebecca Kristeleit, Angela George, Charlie Gourley, Liz-Anne Lewsley, Debbie Rai, Udai Banerji, Samantha Hinsley, Iain A. McNeish

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: